Metabolic reprogramming and angiogenesis in primary cutaneous Merkel cell carcinoma: expression of hypoxia‐inducible factor‐1α and its central downstream factors. (15th June 2020)

• Record Type: Journal Article
• Authors: Toberer, F.; Haenssle, H.A.; Heinzel‐Gutenbrunner, M.; Enk, A.; Hartschuh, W.; Helmbold, P.; Kutzner, H.
• Is Part Of: Journal of the European Academy of Dermatology and Venereology. Volume 35:Number 1(2021)
• Page Start: 88
• Page End: 94
• Publication Date: 2020-06-15
• Subjects: Dermatology -- Periodicals; Sexually transmitted diseases -- Periodicals; 616.5
• DOI: 10.1111/jdv.16600
• Languages: English
• ISSNs: 0926-9959

Abstract

Abstract: Background: Metabolic reprogramming and altered gene expression mediated by hypoxia‐inducible factors play crucial roles during tumour growth and progression. Nevertheless, studies analysing the expression of hypoxia‐inducible factor‐1α and its downstream targets in Merkel cell carcinoma (MCC) are lacking but are warranted to shed more light on MCC pathogenesis and to potentially provide new therapeutic options. Objectives: To analyse the immunohistochemical expression of hypoxia‐inducible factor‐1α (HIF‐1α), vascular endothelial growth factor‐A (referred to as VEGF throughout the manuscript), VEGF receptor‐2 (VEGFR‐2), VEGF receptor‐3 (VEGFR‐3), glucose transporter‐1 (Glut‐1), monocarboxylate transporter 4 (MCT4) and carbonic anhydrase IX (CAIX) in primary cutaneous MCC. Methods: The 16 paraffin‐embedded primary cutaneous MCCs (Merkel cell polyomavirus (McPyV) positive/negative: 11/5) were analysed by immunohistochemistry, namely HIF‐1α, VEGF, VEGFR‐2 (KDR), VEGFR‐3 (FLT4), Glut‐1, MCT4 and CAIX. An established quantification score (QS) was applied to quantitate the protein expression by considering the percentage of positive tumour cells (0: 0%; 1: up to 1%; 2: 2–10%; 3: 11–50%; 4: >50%) in relation to the staining intensity (0: negative; 1: low; 2: medium; 3: strong). Results: HIF‐1α was expressed in all MCCs and predominantly found at the invading edges of tumour margins. The HIF‐1α downstream factors Glut‐1, MCT4 and CAIX were expressed in 13 of 16 MCC (81%), 14 of 16 MCC (88%) and 16 of 16 MCC (100%), respectively. Interestingly, VEGF and VEGFR‐2 were not expressed in tumour cells, whereas VEGFR‐3 was expressed in all MCCs. HIF‐1α was expressed significantly stronger in McPyV + tumours (QS: 10.36 ± 2.41) than in McPyV − tumours (QS: 5.40 ± 1.34; P = 0.002). Similarly, VEGFR‐3 was also expressed significantly stronger in McPyV + tumours (QS: 10.00 ± 2.52) than in McPyV − tumours (QS: 5.40 ± 3.43, P = 0.019). Conclusions: Our data provide first evidence for a role of HIF‐1α in induced metabolic reprogramming contributing to MCC pathogenesis. The metabolic signatures of McPyV + and McPyV − tumours seem to show relevant differences.